- Poster presentation
- Published:
Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital
Critical Care volume 13, Article number: P432 (2009)
Introduction
Recombinant activated factor VII (rFVIIa) is increasingly used for the treatment of acquired coagulopathies associated with uncontrolled haemorrhage. Consensus guidelines [1] have been published for the administration of rFVIIa in this setting. We examined the off-licence use of rFVIIa in our 1,071-bed tertiary referral hospital.
Methods
Hospital blood-bank data were examined from the first off-licence use of rFVIIa in November 2002 until August 2008. Case notes were reviewed on these patients to gain demographics, indications and dosage of rFVIIa. Pathology data were cross-referenced to gain results before and after administration of rFVIIa.
Results
Twenty-two patients were identified over the 6-year period who received off-licence rFVIIa. The majority of uses were in cardiac surgery (nine patients), followed by general/vascular surgery (five patients), and trauma (four patients). Of these patients, 41% (nine patients) did not survive >24 hours. Mean dosage was 7.8 mg (89.4 μg/kg) and was given after mean transfusions of 24.8 units of packed red cells, 13 units of fresh frozen plasma, 3.5 units of pooled platelets and 2 units of cryoprecipitate, in the preceding 24 hours. At this time, blood tests reveal a mean of 91 platelets (SD = 54.9), but nearly one-quarter of patients received the drug with a platelet count <50; prothrombin time 17.9 seconds, activated partial thromboplastin time 58.7 seconds, and pH 7.18. Mean temperature prior to rFVIIa administration was 34.7°C. Full APACHE II data were available for 64% of the patients with a mean of 18.3 (SD = 6.5), and for the trauma patients a mean revised trauma score of 5.9. Following the administration of rFVIIa, the mean prothrombin time reduced to 13.4 seconds at 1 hour. Sixty-eight per cent of patients (15) received blood product transfusions in the immediate 24 hours after having rFVIIa with a mean of 2 units packed red cells, 3.2 units fresh frozen plasma, 1.5 units pooled platelets and 1.1 units cryoprecipitate.
Conclusion
References
Vincent JL, et al.: Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective. Crit Care 2006, 10: R120. 10.1186/cc5026
Stanworth S, et al.: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007, 2: CD005011.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spivey, M., Eve, H. & Duffy, M. Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital. Crit Care 13 (Suppl 1), P432 (2009). https://doi.org/10.1186/cc7596
Published:
DOI: https://doi.org/10.1186/cc7596